Veropharm (Abbott Group) announced the signing of Strategic Partnership Agreement with Bion, a Russian manufacturer of pharmaceutical substances for finished dosage forms.
The long-term strategic partnership will involve the development of high-tech substances to manufacture medicinal products for the treatment of cancer, as well as the diseases of cardiovascular and central nervous system. The drugs will be produced in modern manufacturing facilities of Veropharm (Abbott Group) in Belgorod and Volginsky settlement in Vladimir region.
The medicinal products manufactured on the basis of Bion substances will expand the portfolio of Veropharm (Abbott Group) built as a part of the strategy aimed at providing high quality and affordable medications to the patients.
Strategic partnership will promote the development and realization of scientific and technological potential of Russian pharmaceutical industry.
“Caring about people’s health is at the core of our business. Therefore, the quality and safety of products represent one of the main priorities of Veropharm (Abbott Group). We actively support the idea of introducing the international quality standards in Russia and follow the best international practices in manufacturing of medicines on our plants in Russia. Modern production facilities of Veropharm are equipped in strict compliance with GMP standards, and we pay a particular attention to selecting the manufacturing partners. Our new initiative helps to develop health care industry and contributes to improving the health of the population,” says Elena Yu. Bushberg, the General Director of Veropharm (Abbott Group).
“The level of scientific, technical and manufacturing base, and quality management system in our enterprise fully comply with GMP standards, which allows us to expand cooperation with industry leaders,” said Elena A. Sinchenko, the President of Bion.